Antinuclear Antibodies in Autoimmune Diseases.. | ||||
| Sohag Medical Journal | ||||
| Article 25, Volume 23, Issue 3, July 2019, Page 122-125 PDF (216.4 K) | ||||
| DOI: 10.21608/smj.2019.14992.1024 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Nagwa Abo Elmahassen  1; Zeinab M Mahmoud2; Hesham Hefney1
| ||||
| 1Department of clinical and chemical pathology, Sohag Faculty of Medicine, Sohag University | ||||
| 2Department of clinical and chemical pathology, Sohag Faculty of Medicine, Sohag University. | ||||
| Abstract | ||||
| Autoimmune disorders represent a various cluster of sicknesses portrayed by cell and humoral reactions against self. The humoral immune system reactions are coordinated against differed segments inside the cell and outside the cell. Immune system infections, for example, fundamental lupus erythematosus (SLE), rheumatic inflammatory disease, foundational sclerosis, and antineutrophil cellular material protein related general vasculitis, are more often than not over the span of the frequency of non organ-explicit autoantibodies. Antinuclear antibodies (ANA) may be a term for an outsized and heterogeneous cluster of current antibody. reflective the important uses, ANA are utilized for diagnosing or criteria for lupus, foundational Sclerosis, blended connective tissue infection and undifferentiated connective tissue ailment. ANA have been determined by indirect immunofluorescence measure (IIFA) for quite a long time. Elective procedures were created testing the exemplary IIFA as the interest for ANA testing expanded. These stages vary in their antigen profiles, affectability and particularity, raising vulnerabilities with respect to institutionalization and elucidation of incongruent outcomes. | ||||
| Keywords | ||||
| Ana; classification; detection | ||||
|
Statistics Article View: 220 PDF Download: 299 |
||||
